LT5240B - Polifenolių turinti maistinė farmacinė kompozicija, skirta vėžio gydymui - Google Patents

Polifenolių turinti maistinė farmacinė kompozicija, skirta vėžio gydymui Download PDF

Info

Publication number
LT5240B
LT5240B LT2004076A LT2004076A LT5240B LT 5240 B LT5240 B LT 5240B LT 2004076 A LT2004076 A LT 2004076A LT 2004076 A LT2004076 A LT 2004076A LT 5240 B LT5240 B LT 5240B
Authority
LT
Lithuania
Prior art keywords
pharmaceutical composition
lysine
proline
ascorbate
cancer
Prior art date
Application number
LT2004076A
Other languages
English (en)
Lithuanian (lt)
Other versions
LT2004076A (en
Inventor
Matthias Rath
Shrirang Netke
Aleksandra Niedzwiecki
Original Assignee
Matthias Rath
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23366808&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=LT5240(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Matthias Rath filed Critical Matthias Rath
Publication of LT2004076A publication Critical patent/LT2004076A/xx
Publication of LT5240B publication Critical patent/LT5240B/lt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/105—Plant extracts, their artificial duplicates or their derivatives
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/16—Inorganic salts, minerals or trace elements
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/17—Amino acids, peptides or proteins
    • A23L33/175—Amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/401—Proline; Derivatives thereof, e.g. captopril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Polymers & Plastics (AREA)
  • Food Science & Technology (AREA)
  • Nutrition Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Rheumatology (AREA)
  • Inorganic Chemistry (AREA)
  • Botany (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
LT2004076A 2002-01-11 2004-08-11 Polifenolių turinti maistinė farmacinė kompozicija, skirta vėžio gydymui LT5240B (lt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US34814302P 2002-01-11 2002-01-11

Publications (2)

Publication Number Publication Date
LT2004076A LT2004076A (en) 2005-02-25
LT5240B true LT5240B (lt) 2005-07-25

Family

ID=23366808

Family Applications (1)

Application Number Title Priority Date Filing Date
LT2004076A LT5240B (lt) 2002-01-11 2004-08-11 Polifenolių turinti maistinė farmacinė kompozicija, skirta vėžio gydymui

Country Status (26)

Country Link
US (2) US7041699B2 (de)
EP (1) EP1465614B1 (de)
JP (1) JP2005519055A (de)
KR (1) KR20040073559A (de)
CN (1) CN100377706C (de)
AT (1) ATE382343T1 (de)
AU (1) AU2003235762B2 (de)
BR (1) BR0302672A (de)
CA (1) CA2471932A1 (de)
DE (1) DE60318387T2 (de)
EE (1) EE200400032A (de)
ES (1) ES2298519T3 (de)
HR (1) HRP20040704A2 (de)
HU (1) HUP0500498A3 (de)
IL (1) IL162646A0 (de)
LT (1) LT5240B (de)
LV (1) LV13248B (de)
MX (1) MXPA04006717A (de)
NO (1) NO20033950L (de)
NZ (1) NZ533737A (de)
PL (1) PL215159B1 (de)
RU (1) RU2301666C2 (de)
UA (1) UA80692C2 (de)
WO (1) WO2003057201A2 (de)
YU (1) YU75003A (de)
ZA (1) ZA200405075B (de)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9034310B2 (en) * 2002-02-21 2015-05-19 Stephen B. Cantrell Interferon-statin combination cancer therapy
US7115283B2 (en) * 2003-05-06 2006-10-03 Access Business Group International Llc Preparations for sustained release of nutraceuticals and methods of controllably releasing nutraceuticals
US20040253319A1 (en) * 2003-06-11 2004-12-16 Shrirang Netke Pharmaceutical compositions and method for alleviating side-effects of estrogen replacement therapy
PL1689381T3 (pl) * 2003-09-05 2010-07-30 Matthias Rath Kompozycja farmaceutyczna zawierająca m.in. witaminę C, magnez, wyciąg z zielonej herbaty do hamowania chorób sercowo-naczyniowych (proliferacji SMC)
US20050176674A1 (en) * 2004-02-09 2005-08-11 Friesen Kim G. Composition and method for use in cartilage affecting conditions
US8377904B2 (en) 2004-02-09 2013-02-19 Hill's Pet Nutrition, Inc. Composition and method for use in cartilage affecting conditions
KR100601080B1 (ko) * 2004-08-26 2006-07-19 가톨릭대학교 산학협력단 (-)-에피갈로카테킨 갈레이트를 유효성분으로 하는류마티스성 관절염 치료제
NZ589276A (en) 2005-02-03 2012-06-29 Topotarget Uk Ltd Combination therapies using hdac inhibitors and erlotinib (tarceva)
EP1874354A1 (de) 2005-04-11 2008-01-09 Rath, Matthias Nährstoffzusammensetzung mit polyphenolen von grünem tee zur behandlung von osteosarkom
BRPI0520227A2 (pt) * 2005-04-11 2009-04-22 Matthias Rath uso de uma composiÇço nutriente para o tratamento de sarcoma e cÂncer de pràstata
SI1901729T1 (sl) * 2005-05-13 2012-05-31 Topotarget Uk Ltd Farmacevtske formulacije HDAC inhibitorjev
US8138359B2 (en) * 2005-07-26 2012-03-20 Mitsui Norin Co., Ltd. Stabilized 3-hydroxyflavan compositions and methods therefor
WO2007033356A2 (en) * 2005-09-14 2007-03-22 Mitsui Norin Co., Ltd Compositions and methods for green tea catechins for modification of detoxification enzymes
CA2627923C (en) * 2005-11-10 2016-01-12 Topotarget Uk Limited Histone deacetylase (hdac) inhibitors (pxdlol) for the treatment of cancer
US20070212426A1 (en) * 2006-03-10 2007-09-13 Matthias Rath Composition and method of retarding viral activity and reducing viral replication
WO2007147128A2 (en) * 2006-06-16 2007-12-21 Summa Health System Non-toxic anti-cancer drug combining ascorbate, magnesium and a naphthoquinone
GB0615781D0 (en) * 2006-08-09 2006-09-20 Coressence Ltd Prebiotic composition
US20080114054A1 (en) * 2006-11-14 2008-05-15 Rath Microbes Compositions and methods for reducing antimicrobial resistance of microbes
RU2328282C1 (ru) * 2007-04-23 2008-07-10 Закрытое акционерное общество "МираксБиоФарма" Фармацевтическая композиция для профилактики образования метастазов и повышения чувствительности (сенсибилизации) опухолей к химиотерапевтическим препаратам
US8617544B2 (en) * 2007-05-01 2013-12-31 Richard L. Kozlenko Compositions and methods for controlling lipid metabolism
GB0710536D0 (en) * 2007-06-01 2007-07-11 Veritron Ltd Plant extract and its therapeutic use
CN101868446A (zh) * 2007-09-25 2010-10-20 托波塔吉特英国有限公司 某些异羟肟酸化合物的合成方法
GB0725077D0 (en) * 2007-12-21 2008-01-30 Univ Murcia Antifolate com[ounds for the treatment of melanoma
SI2262493T1 (sl) * 2008-03-07 2015-07-31 Onxeo Dk Branch Of Onxeo S.A. France Postopki zdravljenja z uporabo podaljšane kontinuirane infuzije belinostata
RU2395281C2 (ru) * 2008-09-04 2010-07-27 Всеволод Иванович Киселев Фармацевтическая композиция для лечения диспластических процессов шейки матки
MX2011004678A (es) 2008-11-04 2011-10-11 Vymedic Llc Formulaciones complementarias antivirales.
US8677463B2 (en) * 2008-12-05 2014-03-18 At&T Intellectual Property I, Lp System and method for managing multiple sub accounts within a subcriber main account in a data distribution system
JP2009143928A (ja) * 2008-12-26 2009-07-02 Kyushu Univ ガロイルカテキン類の抗酸化活性の促進方法
GB0900555D0 (en) * 2009-01-14 2009-02-11 Topotarget As New methods
CN105816498A (zh) 2009-04-27 2016-08-03 玫琳凯有限公司 植物性抗痤疮制剂
IT1397522B1 (it) * 2009-12-21 2013-01-16 Solartium Entpr Ltd Uso di una combinazione per il trattamento dell'osteoartrosi
GB201015784D0 (en) 2010-09-20 2010-10-27 Bionature E A Ltd Anti-cancer compounds
WO2013096485A1 (en) 2011-12-19 2013-06-27 Mary Kay Inc. Combination of plant extracts to improve skin tone
RU2522547C1 (ru) * 2012-11-12 2014-07-20 Федеральное государственное бюджетное учреждение "Научно-исследовательский институт онкологии имени Н.Н. Петрова" Министерства здравоохранения Российской Федерации Фармакологическая геропротекторная композиция и способ ее получения
US20140154702A1 (en) * 2012-11-30 2014-06-05 Endocyte, Inc. Methods For Treating Cancer Using Combination Therapies
JP2016519092A (ja) * 2013-03-18 2016-06-30 デンタルメッド ファーム ホールディング リミテッド 組成物におけるn−アセチルシステイン誘導体とクランベリーポリフェノールとの組み合わせ、並びに歯周疾患及びインプラント周囲炎を予防及び処置するための方法
BE1023772B9 (fr) * 2013-05-17 2017-08-02 Valore Composition a base d'un complexe de (+)-catechine et d'acide amine pour le traitement et la prevention du cancer
IN2013MU01528A (de) * 2013-07-26 2015-06-26 Tata Memorial Ct
GB2520794A (en) * 2013-07-26 2015-06-03 Tata Memorial Ct Plant poly-phenol and copper (II) mediated degradation of DNA and RNA
EP3116469B1 (de) 2014-03-10 2018-10-03 Mary Kay, Inc. Hautaufhellungszubereitungen
BE1022579A9 (fr) * 2014-11-10 2016-10-06 Valore Composition antimétastatique comprenant au moins un composé de type flavanol
CN105061533B (zh) * 2015-09-18 2018-02-09 福州大学 六甲氧基二氢黄酮‑鼠李糖基‑鼠李糖苷及其应用
CN106138036A (zh) * 2016-04-29 2016-11-23 陈西敬 抗坏血酸棕榈酸酯在制备抗肿瘤药物中的应用
US11206861B2 (en) * 2016-10-03 2021-12-28 Houn Simon Hsia Compositions and methods for enhancing cancer radiotherapy
US12029765B2 (en) 2017-06-13 2024-07-09 Houn Simon Hsia Compositions and methods for treating cancer
WO2018231943A2 (en) 2017-06-13 2018-12-20 Houn Simon Hsia Compositions and methods for enhancing cancer chemotherapy
KR102775757B1 (ko) 2017-06-13 2025-02-28 호운 사이먼 샤 암 방사선요법을 향상시키기 위한 조성물 및 방법
CN111529709A (zh) * 2020-06-03 2020-08-14 北京易思腾翻译服务有限公司 一种可用于体重控制且可逆转动脉粥样硬化的组合物
WO2022124386A1 (en) * 2020-12-07 2022-06-16 L' Oreal Composition comprising ascorbic acid and cyclic amino acid
IT202200010592A1 (it) * 2022-05-23 2023-11-23 Neilos S R L “Composizione nutraceutica o farmaceutica per l’infertilità maschile”

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5962517A (en) 1997-01-31 1999-10-05 Murad; Howard Pharmaceutical compositions and methods for treating acne
WO2007076492A2 (en) 2005-12-28 2007-07-05 Sandisk Corporation Methods and systems for writing non-volatile memories for increased endurance

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4243363A1 (de) * 1992-12-21 1994-06-23 Ulrich Dr Med Kuebler Behandlungsverfahren für Hauttrockenheit
US5817695A (en) * 1997-12-24 1998-10-06 Pellico; Michael A. Nutritional product with high fat, low carbohydrate and amino acid imbalance
EP0938897A1 (de) * 1997-12-26 1999-09-01 Japanese Foundation For Cancer Research Telomerase Hemmer
AT407821B (de) * 1998-03-24 2001-06-25 Franz Dr Stueckler Mittel auf der basis von naturstoffen
AU4043900A (en) * 1999-03-30 2000-10-16 Purdue Research Foundation Compositions containing tea catechins as cancer specific proliferation inhibitors
KR20020016833A (ko) 1999-06-15 2002-03-06 뉴트리-로직스, 인크. 발병 감소에 유용한 영양 제제, 관련 치료 방법 및 성분스크리닝 방법
US6299925B1 (en) * 1999-06-29 2001-10-09 Xel Herbaceuticals, Inc. Effervescent green tea extract formulation
US6448030B1 (en) * 2000-02-18 2002-09-10 University Of Nevada-Las Vegas Method for predicting the efficacy of anti-cancer drugs
ATE327747T1 (de) * 2000-10-09 2006-06-15 Matthias Dr Med Rath Therapeutische kombination des ascorbats mit lysin und arginin für verhinderung und behandlung des krebses

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5962517A (en) 1997-01-31 1999-10-05 Murad; Howard Pharmaceutical compositions and methods for treating acne
WO2007076492A2 (en) 2005-12-28 2007-07-05 Sandisk Corporation Methods and systems for writing non-volatile memories for increased endurance

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
AHMAD N ET AL.: "Green tea constituent epigallocatechin-3-gallate and induction of apoptosis and cell cycle arrest in human carcinoma cells", J NATL CANCER INST., 1997, pages 1881 - 1886
CAO Y, CAO R.: "Angiogenesis inhibited by drinking tea", NATURE, 1999, pages 381, XP000953295, DOI: doi:10.1038/18793
CHEN L, LEE MJ, LI H, YANG CS.: "Absorption, distribution, elimination of tea polyphenols in rats", DRUG METAB DISPOS., 1997, pages 1045 - 1050, XP055259807
H-H. SHERRY CHOW ET AL.: "Phase I pharmacokinetic study of tea polyphenols following single-dose administration of epigallocatechin gallate and Polyphenon E", CANCER EPIDEMIOL. BIOMARKERS PREV., 2001, pages 53 - 58, XP002366662
JENNIFER RC BELL, ET AL.: "(+)-Catechin in human plasma after ingestion of a single serving of reconstituted red wine1,2,3", AMERICAN SOCIETY FOR CLINICAL NUTRITION, 2000, pages 103 - 108
MUKHTAR H, AHMAD N.: "Tea polyphenols: prevention of cancer and optimizing health.", AM J CLIN NUTR., 2000, pages 1698 - 1702
YANG CS, CHEN L ET AL.: "Blood and urine levels of tea catechins after ingestion of different amounts of green tea by human volunteers", CANCER EPIDEMIOL BIOMARKERS PREV., 1998, pages 351 - 355

Also Published As

Publication number Publication date
HUP0500498A3 (en) 2013-01-28
HK1086489A1 (zh) 2006-09-22
WO2003057201A3 (en) 2004-03-11
EP1465614B1 (de) 2008-01-02
AU2003235762B2 (en) 2008-10-02
KR20040073559A (ko) 2004-08-19
EP1465614A2 (de) 2004-10-13
LV13248B (en) 2005-06-20
NO20033950L (no) 2003-11-10
IL162646A0 (en) 2005-11-20
US7041699B2 (en) 2006-05-09
BR0302672A (pt) 2004-02-25
PL371282A1 (en) 2005-06-13
ES2298519T3 (es) 2008-05-16
JP2005519055A (ja) 2005-06-30
UA80692C2 (en) 2007-10-25
NO20033950D0 (no) 2003-09-05
DE60318387D1 (de) 2008-02-14
MXPA04006717A (es) 2004-11-10
YU75003A (sh) 2006-08-17
WO2003057201A2 (en) 2003-07-17
ATE382343T1 (de) 2008-01-15
US20030170319A1 (en) 2003-09-11
AU2003235762A1 (en) 2003-07-24
ZA200405075B (en) 2006-07-26
CN1731989A (zh) 2006-02-08
HRP20040704A2 (en) 2004-10-31
PL215159B1 (pl) 2013-10-31
NZ533737A (en) 2006-02-24
DE60318387T2 (de) 2008-12-18
RU2004124384A (ru) 2005-04-20
HUP0500498A2 (hu) 2005-08-29
US20060142212A1 (en) 2006-06-29
EE200400032A (et) 2004-04-15
RU2301666C2 (ru) 2007-06-27
CN100377706C (zh) 2008-04-02
LT2004076A (en) 2005-02-25
CA2471932A1 (en) 2003-07-17

Similar Documents

Publication Publication Date Title
US7041699B2 (en) Nutrient pharmaceutical formulation comprising polyphenols and use in treatment of cancer
Seeram et al. In vitro antiproliferative, apoptotic and antioxidant activities of punicalagin, ellagic acid and a total pomegranate tannin extract are enhanced in combination with other polyphenols as found in pomegranate juice
EP1072254A1 (de) Nahrungsmittel, orale zusammensetzungen und medizinische zusammensetzungn zur verhinderung oder behandlung von periodontosis und verfahren zur verhinderung oder behandlung von periodontosis
AU2008203157A1 (en) Composition inhibiting matrix-metallproteinases for the treatment of neoplastic diseases
Papageorgiou et al. Antioxidant treatment and endothelial dysfunction: is it time for flavonoids?
Roomi et al. Antitumor effect of nutrient synergy on human osteosarcoma cells U-2OS, MNNG-HOS and Ewing's sarcoma SK-ES. 1.
Loke et al. Evaluating product demographics, composition and health claims of commercial polyphenol supplements: a review of dosage, bioactive compounds and efficacy
Roomi et al. In vivo and In vitro effect of a nutrient mixture on human hepatocarcinoma cell line SK-HEP-1
HK1086489B (en) A nutrient pharmaceutical formulation comprising polyphenols and use in the manufacture of a medicament for the treatment of cancer
EP1874354A1 (de) Nährstoffzusammensetzung mit polyphenolen von grünem tee zur behandlung von osteosarkom
Roomi et al. Inhibitory effects of a nutrient mixture on human testicular cancer cell line NT 2/DT matrigel invasion and MMP activity
Dziabowska-Grabias et al. Antioxidant Therapy in Inflammatory Bowel Diseases. Antioxidants 2021, 10, 412
CN101180080A (zh) 用于治疗骨肉瘤的包含绿茶多酚的营养组合物
Vijay et al. Pro-apoptotic Effects of Dietary Flavonoids In Oxidative Stress-Induced Cancer
Roomi et al. Vitamin C in Health: Scienti� ic focus on its anti-cancer ef� icacy
Roomi et al. In vivo and in vitro antitumor effect of nutrient synergy on human osteosarcoma cell line MNNG-HOS
Singh et al. Role of Antioxidants in Periodontium
Room et al. Antitumor effect of nutrient synergy on human osteosarcoma cells U-2OS, MNNG-HOS and Ewing's sarcoma SK-ES. 1
WO2006108429A1 (en) Nutrient composition for treating sarcoma and prostate cancer
MATRIX M. Waheed Roomi, Vadim Ivanov, Tatiana Kalinovsky
KR20080016547A (ko) 골육종 치료용 녹차 폴리페놀을 포함하는 영양제 조성물